vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与1ST SOURCE CORP（SRCE）财务数据对比。点击上方公司名可切换其他公司
1ST SOURCE CORP的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.5倍（$113.1M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 8.7%），1ST SOURCE CORP自由现金流更多（$58.1M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 7.8%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
第一来源公司（1st Source Corporation）是总部位于美国印第安纳州南本德的金融服务企业，旗下运营第一来源银行，在印第安纳州和密歇根州拥有81家分支机构，其专业金融团队为飞机、卡车、工程设备提供融资服务，同时还通过第一来源保险板块提供各类保险产品及相关服务。
PBYI vs SRCE — 直观对比
营收规模更大
SRCE
是对方的1.5倍
$75.5M
营收增速更快
PBYI
高出19.0%
8.7%
自由现金流更多
SRCE
多$43.7M
$14.4M
两年增速更快
PBYI
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $113.1M |
| 净利润 | — | $40.0M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 45.4% |
| 净利率 | — | 35.3% |
| 营收同比 | 27.7% | 8.7% |
| 净利润同比 | — | 6.5% |
| 每股收益（稀释后） | $0.26 | $1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISRCE
| Q1 26 | — | $113.1M | ||
| Q4 25 | $75.5M | $110.8M | ||
| Q3 25 | $54.5M | $110.7M | ||
| Q2 25 | $52.4M | $108.2M | ||
| Q1 25 | $46.0M | $104.0M | ||
| Q4 24 | $59.1M | $97.8M | ||
| Q3 24 | $80.5M | $97.9M | ||
| Q2 24 | $47.1M | $97.3M |
净利润PBYISRCE
| Q1 26 | — | $40.0M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $8.8M | $42.3M | ||
| Q2 25 | $5.9M | $37.3M | ||
| Q1 25 | $3.0M | $37.5M | ||
| Q4 24 | — | $31.4M | ||
| Q3 24 | $20.3M | $34.9M | ||
| Q2 24 | $-4.5M | $36.8M |
毛利率PBYISRCE
| Q1 26 | — | — | ||
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — |
营业利润率PBYISRCE
| Q1 26 | — | 45.4% | ||
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | 49.7% | ||
| Q2 25 | 12.7% | 44.5% | ||
| Q1 25 | 8.7% | 45.8% | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | 46.3% | ||
| Q2 24 | -4.6% | 49.1% |
净利率PBYISRCE
| Q1 26 | — | 35.3% | ||
| Q4 25 | — | 37.1% | ||
| Q3 25 | 16.2% | 38.2% | ||
| Q2 25 | 11.2% | 34.5% | ||
| Q1 25 | 6.5% | 36.1% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | 25.2% | 35.7% | ||
| Q2 24 | -9.6% | 37.8% |
每股收益（稀释后）PBYISRCE
| Q1 26 | — | $1.63 | ||
| Q4 25 | $0.26 | $1.67 | ||
| Q3 25 | $0.17 | $1.71 | ||
| Q2 25 | $0.12 | $1.51 | ||
| Q1 25 | $0.06 | $1.52 | ||
| Q4 24 | $0.40 | $1.27 | ||
| Q3 24 | $0.41 | $1.41 | ||
| Q2 24 | $-0.09 | $1.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | — |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $1.3B |
| 总资产 | $216.3M | $9.1B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYISRCE
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | — | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — |
总债务PBYISRCE
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
股东权益PBYISRCE
| Q1 26 | — | $1.3B | ||
| Q4 25 | $130.3M | $1.3B | ||
| Q3 25 | $115.3M | $1.2B | ||
| Q2 25 | $104.7M | $1.2B | ||
| Q1 25 | $97.1M | $1.2B | ||
| Q4 24 | $92.1M | $1.1B | ||
| Q3 24 | $71.1M | $1.1B | ||
| Q2 24 | $48.5M | $1.0B |
总资产PBYISRCE
| Q1 26 | — | $9.1B | ||
| Q4 25 | $216.3M | $9.1B | ||
| Q3 25 | $202.9M | $9.1B | ||
| Q2 25 | $194.9M | $9.1B | ||
| Q1 25 | $196.2M | $9.0B | ||
| Q4 24 | $213.3M | $8.9B | ||
| Q3 24 | $220.7M | $8.8B | ||
| Q2 24 | $205.0M | $8.9B |
负债/权益比PBYISRCE
| Q1 26 | — | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $59.1M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $58.1M |
| 自由现金流率自由现金流/营收 | 19.1% | 51.4% |
| 资本支出强度资本支出/营收 | 0.0% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $361.4M |
8季度趋势，按日历期对齐
经营现金流PBYISRCE
| Q1 26 | — | $59.1M | ||
| Q4 25 | $14.4M | $223.1M | ||
| Q3 25 | $9.7M | $51.0M | ||
| Q2 25 | $14.1M | $44.9M | ||
| Q1 25 | $3.6M | $71.8M | ||
| Q4 24 | $15.6M | $193.9M | ||
| Q3 24 | $11.0M | $68.4M | ||
| Q2 24 | $1.0M | $50.0M |
自由现金流PBYISRCE
| Q1 26 | — | $58.1M | ||
| Q4 25 | $14.4M | $213.0M | ||
| Q3 25 | $9.7M | $47.3M | ||
| Q2 25 | $14.1M | $43.0M | ||
| Q1 25 | $3.6M | $69.3M | ||
| Q4 24 | $15.6M | $181.5M | ||
| Q3 24 | $11.0M | $66.7M | ||
| Q2 24 | $1.0M | $46.4M |
自由现金流率PBYISRCE
| Q1 26 | — | 51.4% | ||
| Q4 25 | 19.1% | 192.2% | ||
| Q3 25 | 17.7% | 42.7% | ||
| Q2 25 | 26.8% | 39.8% | ||
| Q1 25 | 7.7% | 66.6% | ||
| Q4 24 | 26.4% | 185.5% | ||
| Q3 24 | 13.7% | 68.1% | ||
| Q2 24 | 2.1% | 47.7% |
资本支出强度PBYISRCE
| Q1 26 | — | 0.9% | ||
| Q4 25 | 0.0% | 9.1% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.0% | 12.6% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 3.7% |
现金转化率PBYISRCE
| Q1 26 | — | 1.48× | ||
| Q4 25 | — | 5.42× | ||
| Q3 25 | 1.10× | 1.21× | ||
| Q2 25 | 2.41× | 1.20× | ||
| Q1 25 | 1.21× | 1.91× | ||
| Q4 24 | — | 6.17× | ||
| Q3 24 | 0.54× | 1.96× | ||
| Q2 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
